DrugPatentWatch Database Preview

Details for Patent: 7,358,366

« Back to Dashboard

Which drugs does patent 7,358,366 protect, and when does it expire?

Patent 7,358,366 protects AVANDARYL and AVANDIA and is included in two NDAs.

Protection for AVANDARYL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in thirty-six countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 7,358,366

Title:	Thiazolidinedione derivative and its use as antidiabetic
Abstract:	A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione- , maleic acid salt (the "Polymorph") characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm.sup.-1; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm.sup.-1; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0, and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
Inventor(s):	Blackler; Paul David James (Cadiz, ES), Giles; Robert Gordon (Tonbridge, GB), Moore; Stephen (Tonbridge, GB), Sasse; Michael John (Tonbridge, GB)
Assignee:	SmithKline Beecham p.l.c. (Brentford, Middlesex, GB)
Application Number:	11/458,471
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 7,358,366
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 7,358,366

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-001	Nov 23, 2005		DISCN	Yes	No					Y
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-002	Nov 23, 2005		DISCN	Yes	No					Y
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-004	Mar 30, 2007		DISCN	Yes	No					Y
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-003	Nov 23, 2005		DISCN	Yes	No					Y

Foreign Priority and PCT Information for Patent: 7,358,366

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9909471.6	Apr 23, 1999
United Kingdom	9912195.6	May 25, 1999

International Family Members for US Patent 7,358,366

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	1607
Argentina	023560
Argentina	023750
Australia	2755102